Letters to the Editor

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Norway;
Dana-Farber Cancer Institute, Boston, MA;
Lille University Hospital, Lille, France;
Hospital Universitario La Princesa and Hospital Quironsalud, Madrid, Spain;
Alfred Health-Monash University, Melbourne, Australia;
Jagiellonian University Medical College, Krakow, Poland;
National Hospital Organization Okayama Medical Center, Okayama, Japan;
Hôpital Necker-Enfants Malades, Paris, France;
Seoul St. Mary Hospital, The Catholic University of Korea, Seoul, Korea, Republic of (South);
Sanofi CMO, Chilly-Mazarin, France;
Sanofi Global Oncology, Cambridge, MA;
Sanofi R&D, Vitry-sur-Seine, France;
Sanofi R&D, Cambridge, MA;
Sanofi R&D, Cambridge, MA;
Sanofi Global Oncology, Cambridge, MA;
University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
Haematologica Early view Jun 25, 2020 https://doi.org/10.3324/haematol.2020.253450